Blonanserin is a dopamine-D2 and serotonin-S2 antagonist.
Uses
Blonanserin dihydrochloride is a potent and orally active 5-HT2A and dopamine D2 receptor antagonist, with Ki values of 0.812 and 0.142 nM, respectively. Blonanserin dihydrochloride is usually acts as an atypical antipsychotic agent, and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension[1][2].
in vivo
Blonanserin dihydrochloride (Oral gavage; 1 mg/kg; once a day for 14 days) significantly ameliorates the social deficit observed in PCP-administered mice and inhibits the decrease in the levels of Ser897-phosphorylation, but preatment with blonanserin does not affect the social behaviors in saline-administered mice[2].
Animal Model:
Mice received saline or phencyclidine once a day for 14 consecutive days[2]
Dosage:
1 mg/kg
Administration:
Oral gavage; once a day for 14 days
Result:
Had an effect on the social deficit in mice that received repeated PCP administration.
[1] Blonanserin [2] Saori Takeuchi, et al. Blonanserin ameliorates social deficit through dopamine-D 3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. Neurochem Int. 2019 Sep;128:127-134. DOI:10.1016/j.neuint.2019.04.008
